Cargando…

Immune therapies for autoimmune diabetes targeting pathogenic peptide–MHC complexes

Detalles Bibliográficos
Autores principales:	Davidson, Howard W, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816664/ https://www.ncbi.nlm.nih.gov/pubmed/32663282 http://dx.doi.org/10.1093/jmcb/mjaa037

Ejemplares similares

Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes
por: Obarorakpor, Nyerhovwo, et al.
Publicado: (2023)

Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
por: Fane, Lauren S., et al.
Publicado: (2022)

Restricted MHC–peptide repertoire predisposes to autoimmunity
por: Logunova, Nadezda N., et al.
Publicado: (2005)

MHC Class I Immunopeptidome: Past, Present, and Future
por: Yewdell, Jonathan W.
Publicado: (2022)

Visiting Molecular Mimicry Once More: Pathogenicity, Virulence, and Autoimmunity
por: Martins, Yuri Chaves, et al.
Publicado: (2023)

Primer: Immunity and Autoimmunity
por: Pietropaolo, Massimo, et al.
Publicado: (2008)

MHC Class I Regulation: The Origin Perspective
por: Sznarkowska, Alicja, et al.
Publicado: (2020)

Why does the immune system of Atlantic cod lack MHC II?
por: Star, Bastiaan, et al.
Publicado: (2012)

Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes
por: Koch, Katherine S, et al.
Publicado: (2010)

Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases
Publicado: (1995)

Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders
por: Fridkis-Hareli, Masha
Publicado: (2013)

Optimized Peptide–MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells
por: Dolton, Garry, et al.
Publicado: (2018)

Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases
por: Serra, Pau, et al.
Publicado: (2021)

Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes
Publicado: (1992)

Tregs with an MHC class II peptide–specific chimeric antigen receptor prevent autoimmune diabetes in mice
por: Spanier, Justin A., et al.
Publicado: (2023)

Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes
por: Spanier, Justin A., et al.
Publicado: (2023)

Weak Proinsulin Peptide–Major Histocompatibility Complexes Are Targeted in Autoimmune Diabetes in Mice
por: Levisetti, Matteo G., et al.
Publicado: (2008)

Autoimmune Responses in the Rheumatoid Synovium
por: Toes, Rene E. M, et al.
Publicado: (2009)

The Repertoires of Peptides Presented by MHC-II in the Thymus and in Peripheral Tissue: A Clue for Autoimmunity?
por: Collado, Javier A., et al.
Publicado: (2013)

Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection
Publicado: (1992)

T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen
Publicado: (1993)

Targeting cancers through TCR-peptide/MHC interactions
por: He, Qinghua, et al.
Publicado: (2019)

Nutrition, the visceral immune system, and the evolutionary origins of pathogenic obesity
por: West-Eberhard, Mary Jane
Publicado: (2019)

MHC Class II Presentation in Autoimmunity
por: Ishina, Irina A., et al.
Publicado: (2023)

Regulation of MHC Class II-Peptide Complex Expression by Ubiquitination
por: Cho, Kyung-Jin, et al.
Publicado: (2013)

Molecular mechanism of peptide editing in the tapasin–MHC I complex
por: Fisette, Olivier, et al.
Publicado: (2016)

Proofreading of Peptide—MHC Complexes through Dynamic Multivalent Interactions
por: Thomas, Christoph, et al.
Publicado: (2017)

Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide–MHC Complexes for T-Cell Receptor Immunotherapy
por: Lorenz, Felix K.M., et al.
Publicado: (2017)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology
por: Guan, Hong-Zhi, et al.
Publicado: (2016)

Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines
por: Umeshappa, Channakeshava Sokke, et al.
Publicado: (2019)

"T-bet"-ing on autoimmunity variants
por: Nguyen, Michelle L. T., et al.
Publicado: (2017)

Dry eye disease immune responses and topical therapy
por: McMonnies, Charles W.
Publicado: (2019)

Vasoactive neuropeptides in clinical ophthalmology: An association with autoimmune retinopathy?
por: Staines, Donald R, et al.
Publicado: (2009)

Association between Microorganisms and Microplastics: How Does It Change the Host–Pathogen Interaction and Subsequent Immune Response?
por: Yang, Wenjie, et al.
Publicado: (2023)

IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity
Publicado: (1996)

Conformational changes and flexibility in T-cell receptor recognition of peptide–MHC complexes
por: Armstrong, Kathryn M., et al.
Publicado: (2008)

A geometric and algebraic view of MHC-peptide complexes and their binding properties
por: Cano, Pedro, et al.
Publicado: (2001)

Opening opportunities for K(d) determination and screening of MHC peptide complexes
por: Kopicki, Janine-Denise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hcauhqj70nq6lvgfkboano13ct